Approved — U.S. FDA (2026-10-26), HRR gene-mutated metastatic hormone-sensitive prostate cancer Europe — under EMA review Japan — approved in 2024 for BRCA-mutated prostate cancer and others; this setting not yet announced
This is new prostate cancer drug news. On October 26, 2026, the U.S. FDA approved the oral targeted drug talazoparib (Talzenna) with enzalutamide (Xtandi) for metastatic hormone-sensitive prostate cancer with HRR gene mutations. In the phase 3 TALAPRO-3 trial, the combination lowered the risk of imaging-confirmed progression or death by 52%, and 76.6% of patients were free of progression at three years.
What was newly approved: the combination moves to an earlier stage
Talazoparib is a PARP inhibitor. It blocks PARP, an enzyme cancer cells use to repair damaged DNA, so tumor cells that already have weak DNA repair cannot survive. Enzalutamide is a hormonal drug that blocks male hormone signaling, and the two drugs are known to strengthen each other’s effect.
In the United States the combination was already approved in 2023 for the castration-resistant stage, when the cancer grows despite hormone therapy, in patients with HRR-mutated metastatic prostate cancer. The new approval lets the same combination be used earlier, while the cancer still responds to hormone therapy. The results were presented at the 2026 American Society of Clinical Oncology (ASCO) meeting and published in NEJM.
Who is eligible: HRR mutation confirmed by genetic testing
According to the FDA label, the combination is for adults with prostate cancer that has spread to bone or other organs and is androgen pathway modulation-naive or -sensitive. An FDA-authorized test must also confirm an HRR (homologous recombination repair) gene mutation.
- HRR genes include DNA repair genes such as BRCA1, BRCA2, ATM and CDK12.
- According to Pfizer, about 25% of patients at this stage carry an HRR mutation.
- A tissue test (FoundationOne CDx) and a blood test (FoundationOne Liquid CDx) were approved as companion diagnostics.
- During treatment patients continue a GnRH analog injection or have had both testicles removed.
This is why genetic testing early after diagnosis matters. The result can also guide genetic counseling for family members.
TALAPRO-3 results: 76.6% progression-free at 3 years
The evidence comes from TALAPRO-3 (NCT04821622), an international randomized double-blind phase 3 trial. It assigned 599 patients with HRR mutations from the U.S., Canada, Europe, South America and the Asia-Pacific region 1:1 to talazoparib or placebo. Both groups also received enzalutamide 160 mg and standard hormone therapy.
| Measure | Talazoparib combination | Placebo combination |
|---|---|---|
| Median radiographic progression-free survival | Not reached | 45.8 months |
| Hazard ratio for progression or death | 0.48 (95% CI 0.36–0.65) — 52% lower risk | |
| Progression-free at 3 years | 76.6% | 56.2% |
| Hazard ratio, BRCA mutations | 0.37 (95% CI 0.22–0.61) | |
| Hazard ratio, non-BRCA HRR mutations | 0.57 (95% CI 0.39–0.82) | |
| Hazard ratio, time to PSA progression | 0.51 (95% CI 0.37–0.71) | |
| 3-year survival (interim) | 78% | 72% |
Sources: FDA approval reports in Targeted Oncology and CancerNetwork (2026-10-26) and UroToday’s ASCO 2026 summary. A hazard ratio below 1 favors the combination.
Progression-free survival is the time patients live without the cancer growing or spreading on scans. In the combination group the median was not reached during follow-up, and benefit was seen with both BRCA and other HRR mutations. Time until the next treatment was also longer. Overall survival is still being followed: at the interim analysis three-year survival was 6 percentage points higher with the combination, but the difference was not yet statistically confirmed.
Anemia and how it is managed: regular blood tests are key
Anemia was the most common side effect. It occurred in 71% of the combination group (22% with placebo), and grade 3 or higher anemia in 51% (3% with placebo). Severe anemia usually appeared at a median of 3.2 months, and 40% of patients received a transfusion. Fatigue, low neutrophils and weakness were also reported.
These side effects can be managed when planned for. Blood counts are checked often early in treatment, and if anemia develops the drug is paused or the dose lowered, with transfusion when needed. In the trial 5% of patients stopped talazoparib because of anemia, and most continued with dose adjustment. Patient-reported quality of life showed no clear decline apart from reduced appetite. Rare cases of myelodysplastic syndrome or acute myeloid leukemia (5 patients in the combination group) are listed as warnings.
Where it is available: approved in the U.S., under review in Europe
- United States: FDA approval on October 26, 2026 (approved treatment), after priority review.
- Europe: The European Medicines Agency (EMA) is reviewing the same indication.
- Canada and Australia: Regulators are reviewing it through the international Project Orbis program.
- Japan: Talazoparib was approved in January 2024 for certain BRCA-mutated breast and prostate cancers and launched that April. As of the date we checked, no Japanese approval has been announced for this hormone-sensitive setting.
Approval scope and insurance coverage differ by country, so check the local approval and costs first if you are considering treatment abroad. For radiation options in localized disease see our prostate cancer proton therapy guide, and for reading Japanese medical information see other Japan medical information.
What to check and questions for your doctor
- Has my cancer been tested for BRCA or other HRR gene mutations? If not, can I be tested now with tissue or blood?
- Is my disease hormone-sensitive or castration-resistant?
- How often will I need blood tests if I start the combination?
- If anemia develops, how are dose changes and transfusions decided?
- Should my family members have genetic counseling or testing?
Frequently asked questions
Which prostate cancer patients can receive talazoparib with enzalutamide?
Under the FDA label, adults with metastatic prostate cancer that still responds to hormone therapy and has an HRR gene mutation confirmed by an approved test. Standard hormone therapy (GnRH analog or orchiectomy) continues alongside.
How effective was the new prostate cancer drug talazoparib?
In TALAPRO-3 the risk of imaging progression or death was 52% lower (hazard ratio 0.48), and 76.6% versus 56.2% were progression-free at three years. Benefit was reported with both BRCA and other HRR mutations.
What are the side effects of talazoparib and how are they managed?
Anemia is the most common, with grade 3 or higher in 51%. It is managed with regular blood tests, treatment breaks, dose reduction and transfusion when needed; 5% stopped the drug because of anemia.
Is this combination available in Japan?
Talazoparib was approved in Japan in 2024 for certain BRCA-mutated breast and prostate cancers. As of the check date (2026-10-29), no Japanese approval has been announced for the hormone-sensitive setting.
Related: Savolitinib combination after Tagrisso resistance · Prostate cancer proton therapy · All cancer type articles
Sources
- Targeted Oncology — FDA approves talazoparib/enzalutamide in HRR-mutated prostate cancer (2026-10-26)
targetedonc.com
Checked: 2026-10-29 - CancerNetwork — FDA approves talazoparib/enzalutamide for HRR gene-altered metastatic prostate cancer (2026-10-26)
cancernetwork.com
Checked: 2026-10-29 - Pfizer — TALZENNA plus XTANDI FDA-approved for an earlier metastatic prostate cancer treatment setting (2026-10-26)
biospace.com
Checked: 2026-10-29 - UroToday — ASCO 2026: TALAPRO-3, talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR gene alterations
urotoday.com
Checked: 2026-10-29 - Agarwal N, et al. PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer. N Engl J Med 2026;395:427-439
doi.org/10.1056/NEJMoa2604126
Checked: 2026-10-29 - ClinicalTrials.gov — NCT04821622: TALAPRO-3
clinicaltrials.gov/study/NCT04821622
Checked: 2026-10-29 - PHARMACY JOURNAL (Japan) — Pfizer Japan launches talazoparib (2024-04-24, in Japanese)
pj.jiho.jp
Checked: 2026-10-29
Written by the FTH editorial team. Sources checked 2026-10-29 · Medical review: not applicable
This article is general information based on public sources and does not replace diagnosis or treatment. Please discuss treatment decisions with your medical team.
